Table 1.
Compact summary of the oncological aspects of 300 patients undergoing curative surgery for stage I non-small cell lung cancer (NSCLC). Abbreviations: BMI, body mass index; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; ASA, American Society of Anesthesiologists physical status classification system.
| Criterion | Value |
|---|---|
| Number of patients | 300 |
| Age | 65.4 ± 10.0 (20–87) |
| Male/Female | 187 (62.3%)/113 (37.7%) |
| BMI | 26.3 ± 4.3 (15.7–9.5) |
| Death | 73 (24.3%) |
| Death due to tumor | 38 (12.7%) |
| Death not tumor related | 35 (11.7%) |
| Tumor recurrence | 59 (19.7%) |
| Postoperative tumor size | |
| T1a | 116 (38.7%) |
| T1b | 78 (26.0%) |
| T2 | 106 (35.3%) |
| Albumin (g/dL) | 4.29 ± 0.49 (2.3–5.4) |
| CRP (mg/L) | 7.88 ± 15.80 (0.5–135.6) |
| GPS | |
| 0 | 229 (76.3%) |
| 1 | 68 (22.7%) |
| 2 | 3 (1.0%) |
| ASA | |
| 1 | 7 (2.3%) |
| 2 | 101 (33.7%) |
| 3 | 173 (57.7%) |
| 4 | 19 (6.3%) |
| Follow-up time (months) | 38.1 ± 28.3 (0–123) |
| Overall survival | |
| 1 year | 94.2% ± 1.4% |
| 3 year | 80.8% ± 2.7% |
| 5 year | 72.5% ± 3.5% |
| 10 year | 29.0% ± 9.2% |